Over the past 20 years, the rheumatoid arthritis (RA) treatment landscape has been continuously evolving. A range of novel biologic agents, different from the conventional therapies, became available. However, some understandable concerns, such as long-term safety, accompanied their development. Over the years in rheumatology research, I aimed to broaden the knowledge of the new treatments of RA through real-word research, which proved to be valuable in providing important evidence to clinicians and enabling them to make informed treatment decisions. Nevertheless, many unanswered questions remain-it will be interesting to see how the research progresses over the next 20 years.
Keywords: Biologics; Editorial; Meta-analysis; Real-world research; Rheumatoid arthritis; Safety.